GoodRx (GDRX, $49.32) surges in first trading day
GoodRx soared in its debut trading Wednesday on the Nasdaq.
The company, a digital prescription price comparison and coupon provider, saw its stock recently traded at $48.45, up +46.81% from its initial public offering price of $33, which in turn was well above the $24 to $28 range set by the underwriters.
Inn the six months ended June 30, GoodRx’s net income totaled $54.7 million, up from $31.2 million a year earlier. Revenue of $256.7 million was higher than $173.2 million a year earlier.
Co-founders and CEOs Doug Hirsch and Trevor Bezdek wrote in the prospectus that “so far, we’ve saved Americans an estimated $20 billion on prescriptions and medical services. We have helped a lot of people save money on their care.” They further noted, “our research indicates that, of our total consumer base, approximately 18 million people got care they otherwise could not afford. We also work closely with physicians and pharmacists - America’s healthcare heroes - to provide research and tools that improve access to care every day,”.
“When patients have exhausted other options, our corporate philanthropy arm, GoodRxHelps, provides free prescriptions and medical services in partnership with clinics across America. We are proud of our focus on minority communities, who face disproportionately greater challenges in obtaining affordable care,” the CEOs added.
GDRX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GDRX turned positive on June 29, 2026. Looking at past instances where GDRX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 23, 2026. You may want to consider a long position or call options on GDRX as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GDRX advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 141 cases where GDRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for GDRX moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
GDRX broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GDRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.612) is normal, around the industry mean (7.813). P/E Ratio (49.333) is within average values for comparable stocks, (53.848). GDRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.280). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (1.305) is also within normal values, averaging (6.086).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GDRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement